Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of HS-20093 versus gemcitabine + docetaxel in osteosarcoma after failure of at least second-line therapy
CTR20251474Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risvutatug rezetecan in osteosarcoma (OS), sponsored by Hansoh Pharmaceutical Group. Started May 2025; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on CTR20251474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251474.